Earthworm.

Earthworm-derived enzyme preparations and nattokinase are the two ingredients most often marketed for fibrinolytic activity, and they are frequently combined in the same capsule. Where two ingredients push the same direction on clot handling, the combined effect on bleeding risk is the thing to watch, particularly alongside anticoagulant or antiplatelet medication. That caution matters more than any claimed additive benefit. Anyone on such medication should raise it with their prescriber before combining these.

EPA competes with arachidonic acid in eicosanoid production and reduces platelet aggregation, while earthworm protease preparations act on fibrin. Different mechanisms, same direction. The relevant point is cumulative effect on bleeding tendency rather than any joint benefit. This is a flag to combine cautiously, not a recommendation to pair.

Adding ginkgo to a fibrinolytic enzyme preparation stacks two ingredients that both lean toward reduced clot formation. Case reports of bleeding events with ginkgo alongside anticoagulants are what make this worth flagging. The combination has not been studied together. Read the pairing as a caution rather than a stack.

Aged and fresh garlic preparations both show antiplatelet activity, and the effect adds to anything else pointing the same way. With an earthworm protease preparation in the same regimen, the combined effect on bleeding is the question. There is no evidence of benefit from combining them. Note it, space it, and discuss with a prescriber if anticoagulants are involved.

Systemic enzyme products commonly combine several proteases, and bromelain is the usual plant-derived member of that group. They share the same formulation problem: gastric acid and pancreatic proteases degrade them unless the dose is enteric coated and taken away from food. Bromelain also has its own platelet effects, which adds to the bleeding caution. The combination is formulation convention.

The one human study in this candidate set gave an earthworm protein supplement together with a bacterial strain, so the two were assessed as a combination rather than separately. That design means the contribution of each component cannot be separated from the result. It supports combining them only in the sense that they have been given together. It does not establish that either drives the effect.

An added protease blend acts on the earthworm protein just as it acts on any other dietary protein, breaking it into peptides and amino acids. That is the opposite of what an enteric-coated enzyme product is trying to achieve. If the aim is intact enzyme delivery past the stomach, do not pair it with a broad protease blend. If the aim is amino acid nutrition, it makes no difference.

Vitamin K is the cofactor for gamma-carboxylation of clotting factors II, VII, IX and X. An earthworm enzyme preparation is marketed for the opposite side of clot handling. The two do not cancel in any measurable, predictable way, but the directions are opposed and worth naming in a formula that contains both. Neither should be assumed to offset the other.

Where earthworm material is used as a protein hydrolysate rather than as an enzyme preparation, it behaves as ordinary dietary protein. In that use it sits alongside collagen peptides without interaction, contributing amino acids. The two are not interchangeable in amino acid profile. Nothing about the pairing is special beyond both being hydrolysates.